Antonio Cuadrado

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4045088/publications.pdf

Version: 2024-02-01

114 papers	15,432 citations	16451 64 h-index	21540 114 g-index
116 all docs	116 docs citations	116 times ranked	19407 citing authors

#	Article	IF	Citations
1	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nature Reviews Drug Discovery, 2019, 18, 295-317.	46.4	849
2	SCF/Î²-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner. Molecular and Cellular Biology, 2011, 31, 1121-1133.	2.3	647
3	Regulation of Heme Oxygenase-1 Expression through the Phosphatidylinositol 3-Kinase/Akt Pathway and the Nrf2 Transcription Factor in Response to the Antioxidant Phytochemical Carnosol. Journal of Biological Chemistry, 2004, 279, 8919-8929.	3.4	642
4	Clinical Relevance of Biomarkers of Oxidative Stress. Antioxidants and Redox Signaling, 2015, 23, 1144-1170.	5.4	604
5	Nrf2 is controlled by two distinct Î²-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene, 2013, 32, 3765-3781.	5.9	500
6	Glycogen Synthase Kinase-3Î² Inhibits the Xenobiotic and Antioxidant Cell Response by Direct Phosphorylation and Nuclear Exclusion of the Transcription Factor Nrf2. Journal of Biological Chemistry, 2006, 281, 14841-14851.	3.4	441
7	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews, 2018, 70, 348-383.	16.0	441
8	The Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation. Journal of Immunology, 2008, 181, 680-689.	0.8	424
9	Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-20.	4.0	390
10	Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/Î²-TrCP Axis. Molecular and Cellular Biology, 2012, 32, 3486-3499.	2.3	338
11	Inflammation in Parkinsonâ€™s Disease: Mechanisms and Therapeutic Implications. Cells, 2020, 9, 1687.	4.1	334
12	Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease. Molecular Pharmacology, 2011, 79, 964-973.	2.3	305
13	Activation of Akt/Protein Kinase B by G Protein-coupled Receptors. Journal of Biological Chemistry, 1998, 273, 19080-19085.	3.4	303
14	Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 2010, 58, 588-598.	4.9	301
15	Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy, 2016, 12, 1902-1916.	9.1	300
16	Pharmacological Targeting of the Transcription Factor Nrf2 at the Basal Ganglia Provides Disease Modifying Therapy for Experimental Parkinsonism. Antioxidants and Redox Signaling, 2011, 14, 2347-2360.	5.4	271
17	Transcription Factors NRF2 and NF-Î²B Are Coordinated Effectors of the Rho Family, GTP-binding Protein RAC1 during Inflammation. Journal of Biological Chemistry, 2014, 289, 15244-15258.	3.4	262
18	Redox Control of Microglial Function: Molecular Mechanisms and Functional Significance. Antioxidants and Redox Signaling, 2014, 21, 1766-1801.	5.4	261

#	Article	IF	Citations
19	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). Redox Biology, 2017, 13, 94-162.	9.0	242
20	Nerve Growth Factor Protects against 6-Hydroxydopamine-induced Oxidative Stress by Increasing Expression of Heme Oxygenase-1 in a Phosphatidylinositol 3-Kinase-dependent Manner. Journal of Biological Chemistry, 2003, 278, 13898-13904.	3.4	238
21	Î±-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics, 2012, 21, 3173-3192.	2.9	228
22	Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease. Antioxidants and Redox Signaling, 2016, 25, 61-77.	5.4	209
23	GSKâ€3Î² downâ€regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. Journal of Neurochemistry, 2008, 105, 192-202.	3.9	208
24	Antioxidants in Translational Medicine. Antioxidants and Redox Signaling, 2015, 23, 1130-1143.	5.4	201
25	Prolonged oral cannabinoid administration prevents neuroinflammation, lowers Î²-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of Neuroinflammation, 2012, 9, 8.	7.2	196
26	Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/Î²-TrCP. Free Radical Biology and Medicine, 2015, 88, 147-157.	2.9	196
27	Regulation of Cu/Zn-Superoxide Dismutase Expression via the Phosphatidylinositol 3 Kinase/Akt Pathway and Nuclear Factor-Î°B. Journal of Neuroscience, 2004, 24, 7324-7334.	3.6	194
28	Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases. Current Drug Targets, 2010, 11, 1517-1531.	2.1	192
29	Inhibition of PKB/Akt1 by C2-Ceramide Involves Activation of Ceramide-Activated Protein Phosphatase in PC12 Cells. Molecular and Cellular Neurosciences, 2000, 15, 156-169.	2.2	183
30	Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radical Biology and Medicine, 2012, 52, 473-487.	2.9	177
31	NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biology, 2017, 13, 444-451.	9.0	161
32	Can Activation of NRF2 Be a Strategy against COVID-19?. Trends in Pharmacological Sciences, 2020, 41, 598-610.	8.7	161
33	Ceramide and Reactive Oxygen Species Generated by H2O2 Induce Caspase-3-independent Degradation of Akt/Protein Kinase B. Journal of Biological Chemistry, 2002, 277, 42943-42952.	3.4	160
34	Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood, 2004, 104, 619-625.	1.4	158
35	Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections. Current Pharmaceutical Design, 2008, 14, 429-442.	1.9	152
36	Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biology, 2017, 11, 543-553.	9.0	147

#	Article	IF	Citations
37	Effect of the Alzheimer amyloid fragment AÎ²(25â€“35) on Akt/PKB kinase and survival of PC12 cells. Journal of Neurochemistry, 2001, 78, 1000-1008.	3.9	142
38	Redox control of protein degradation. Redox Biology, 2015, 6, 409-420.	9.0	138
39	Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. Autophagy, 2018, 14, 1310-1322.	9.1	134
40	Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biology, 2018, 14, 522-534.	9.0	125
41	Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: Modulation by the Nrf2/Trx axis. Free Radical Biology and Medicine, 2010, 48, 1370-1381.	2.9	120
42	Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. Antioxidants and Redox Signaling, 2015, 23, 1171-1185.	5.4	120
43	The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opinion on Therapeutic Targets, 2009, 13, 319-329.	3.4	119
44	Different Susceptibility to the Parkinson's Toxin MPTP in Mice Lacking the Redox Master Regulator Nrf2 or Its Target Gene Heme Oxygenase-1. PLoS ONE, 2010, 5, e11838.	2.5	118
45	Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal celldeath. Molecular and Cellular Neurosciences, 2008, 39, 125-132.	2.2	112
46	Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain, 2014, 137, 78-91.	7.6	112
47	Interleukin-1Î² Enhances GABAA Receptor Cell-surface Expression by a Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2006, 281, 14632-14643.	3.4	111
48	Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology, 2013, 38, 2010-2022.	2.7	108
49	The PTEN/NRF2 Axis Promotes Human Carcinogenesis. Antioxidants and Redox Signaling, 2014, 21, 2498-2514.	5.4	104
50	Role of microglial redox balance in modulation of neuroinflammation. Current Opinion in Neurology, 2009, 22, 308-314.	3.6	100
51	Protein kinase Akt/PKB phosphorylates heme oxygenaseâ€1 in vitro and in vivo. FEBS Letters, 2004, 578, 90-94.	2.8	97
52	Deficiency of Nrf2 Accelerates the Effector Phase of Arthritis and Aggravates Joint Disease. Antioxidants and Redox Signaling, 2011, 15, 889-901.	5.4	93
53	Neuroprotective effect of melatonin against ischemia is partially mediated by alphaâ€7 nicotinic receptor modulation and <scp>HO</scp>â€1 overexpression. Journal of Pineal Research, 2014, 56, 204-212.	7.4	93
54	Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biology, 2018, 18, 173-180.	9.0	84

#	Article	IF	Citations
55	Effects of Nrf2 Deficiency on Bone Microarchitecture in an Experimental Model of Osteoporosis. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-9.	4.0	83
56	Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice. Molecular Neurobiology, 2016, 53, 3030-3045.	4.0	82
57	Nrf2 deficiency potentiates methamphetamineâ€induced dopaminergic axonal damage and gliosis in the striatum. Glia, 2011, 59, 1850-1863.	4.9	79
58	Protein tyrosine phosphatase 1B modulates GSK3Î²/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity. Cell Death and Disease, 2013, 4, e626-e626.	6.3	75
59	Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxidants and Redox Signaling, 2015, 23, 1113-1129.	5.4	75
60	A role for APP in Wnt signalling links synapse loss with Î²-amyloid production. Translational Psychiatry, 2018, 8, 179.	4.8	74
61	Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Experimental Neurology, 2007, 208, 120-126.	4.1	71
62	Inhibition of Heme Oxygenase-1 Interferes with the Transforming Activity of the Kaposi Sarcoma Herpesvirusencoded G Protein-coupled Receptor. Journal of Biological Chemistry, 2006, 281, 11332-11346.	3.4	70
63	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	16.0	70
64	Transcription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippocampus. Redox Biology, 2017, 13, 393-401.	9.0	69
65	The purinergic P2Y13 receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. Free Radical Biology and Medicine, 2010, 49, 416-426.	2.9	68
66	Activation of autophagy in macrophages by pro-resolving lipid mediators. Autophagy, 2015, 11, 1729-1744.	9.1	65
67	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. Antioxidants and Redox Signaling, 2018, 28, 852-872.	5.4	62
68	Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-ÎºB through an AKT/P70S6K/p38-MAPK pathway. Oncogene, 2002, 21, 3739-3753.	5.9	60
69	Discovery of the first dual GSK3Î² inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 45701.	3.3	59
70	Signaling through the Leukocyte Integrin LFA-1 in T Cells Induces a Transient Activation of Rac-1 That Is Regulated by Vav and PI3K/Akt-1. Journal of Biological Chemistry, 2004, 279, 16194-16205.	3.4	58
71	Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. Journal of Neurochemistry, 2007, 102, 1842-1852.	3.9	57
72	Nuclear Import and Export Signals Control the Subcellular Localization of Nurr1 Protein in Response to Oxidative Stress*. Journal of Biological Chemistry, 2013, 288, 5506-5517.	3.4	57

#	Article	IF	Citations
73	Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress. Neuroscience Letters, 2008, 447, 167-171.	2.1	56
74	The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSKâ€3beta: connecting neurotransmission with neuroprotection. Journal of Neurochemistry, 2009, 110, 1107-1119.	3.9	55
75	Nordihydroguaiaretic Acid: From Herbal Medicine to Clinical Development for Cancer and Chronic Diseases. Frontiers in Pharmacology, 2020, 11, 151.	3.5	55
76	Akt1/PKBÎ± Protects PC12 Cells against the Parkinsonism-Inducing Neurotoxin 1-Methyl-4-phenylpyridinium and Reduces the Levels of Oxygen-Free Radicals. Molecular and Cellular Neurosciences, 2001, 17, 67-77.	2.2	54
77	Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1â€independent manner. Molecular Nutrition and Food Research, 2015, 59, 1431-1442.	3.3	53
78	Nrf2-mediated haeme oxygenase-1 up-regulation induced by cobalt protoporphyrin has antinociceptive effects against inflammatory pain in the formalin test in mice. Pain, 2008, 137, 332-339.	4.2	52
79	Agmatine Induces Nrf2 and Protects Against Corticosterone Effects in Hippocampal Neuronal Cell Line. Molecular Neurobiology, 2015, 51, 1504-1519.	4.0	52
80	Regulation of heme oxygenase-1 gene expression through the phosphatidylinositol 3-kinase/PKC-Î¶ pathway and Sp1. Free Radical Biology and Medicine, 2006, 41, 247-261.	2.9	51
81	WNT-3A Regulates an Axin1/NRF2 Complex That Regulates Antioxidant Metabolism in Hepatocytes. Antioxidants and Redox Signaling, 2015, 22, 555-571.	5.4	50
82	Essential role of Nrf2 in the protective effect of lipoic acid against lipoapoptosis in hepatocytes. Free Radical Biology and Medicine, 2015, 84, 263-278.	2.9	50
83	Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage. Trends in Endocrinology and Metabolism, 2019, 30, 312-327.	7.1	50
84	Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. European Journal of Neuroscience, 2006, 24, 1874-1884.	2.6	49
85	Heme oxygenase-1 induction modulates microsomal prostaglandin E synthase-1 expression and prostaglandin E2 production in osteoarthritic chondrocytes. Biochemical Pharmacology, 2009, 77, 1806-1813.	4.4	39
86	Melatoninâ€“sulforaphane hybrid <scp>ITH</scp>12674 induces neuroprotection in oxidative stress conditions by a â€˜drugâ€“prodrugâ€™ mechanism of action. British Journal of Pharmacology, 2015, 172, 1807-1821.	5.4	36
87	Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common Strategy for Neurodegenerative Diseases. Annual Review of Pharmacology and Toxicology, 2022, 62, 255-277.	9.4	33
88	Nrf2 protects the lung against inflammation induced by titanium dioxide nanoparticles: A positive regulator role of Nrf2 on cytokine release. Environmental Toxicology, 2015, 30, 782-792.	4.0	28
89	Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors. Free Radical Biology and Medicine, 2022, 187, 72-91.	2.9	28
90	Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas. Redox Biology, 2020, 30, 101425.	9.0	26

#	Article	IF	Citations
91	Partial elimination of G1 and G2 periods in higher plant cells by increasing the S period. Experimental Cell Research, 1983, 148, 273-280.	2.6	25
92	Xanthine oxidase-derived extracellular superoxide anions stimulate activator protein 1 activity and hypertrophy in human vascular smooth muscle via c-Jun N-terminal kinase and p38 mitogen-activated protein kinases. Journal of Hypertension, 2007, 25, 609-618.	0.5	25
93	Haeme oxygenase-1 overexpression via nAChRs and the transcription factor Nrf2 has antinociceptive effects in the formalin test. Pain, 2009, 146, 75-83.	4.2	21
94	NRF2 in neurodegenerative diseases. Current Opinion in Toxicology, 2016, 1, 46-53.	5.0	19
95	Expression of protein kinase C I in NIH 3T3 cells increases its growth response to specific activators. FEBS Letters, 1990, 260, 281-284.	2.8	16
96	Emerging Therapeutic Targets in Oncologic Photodynamic Therapy. Current Pharmaceutical Design, 2019, 24, 5268-5295.	1.9	15
97	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. European Journal of Medicinal Chemistry, 2020, 190, 112090.	5.5	15
98	Perspectives on the Clinical Development of NRF2-Targeting Drugs. Handbook of Experimental Pharmacology, 2020, 264, 93-141.	1.8	14
99	Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacological Research, 2020, 152, 104597.	7.1	13
100	Cell size of proliferating plant cells increases with temperature: Implications in the control of cell division. Experimental Cell Research, 1989, 185, 277-282.	2.6	11
101	The probability of G1 cells to enter into S increases with their size while S length decreases with cell enlargement in Allium cepa. Experimental Cell Research, 1990, 191, 163-170.	2.6	9
102	TAZ Represses the Neuronal Commitment of Neural Stem Cells. Cells, 2020, 9, 2230.	4.1	9
103	NRF2 and Primary Cilia: An Emerging Partnership. Antioxidants, 2020, 9, 475.	5.1	8
104	Î±-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. Molecular Neurobiology, 2021, 58, 6697-6711.	4.0	8
105	An inhibitor of interaction between the transcription factor NRF2 and the E3 ubiquitin ligase adapter Î²-TrCP delivers anti-inflammatory responses in mouse liver. Redox Biology, 2022, 55, 102396.	9.0	8
106	Transcription Factor NRF2 Participates in Cell Cycle Progression at the Level of G1/S and Mitotic Checkpoints. Antioxidants, 2022, 11, 946.	5.1	7
107	Acylphosphatase synergizes with progesterone during maturation ofXenopus laevisoocytes. FEBS Letters, 1993, 327, 265-270.	2.8	6
108	Influence of cell size on differentiation of root meristem cells. Environmental and Experimental Botany, 1987, 27, 273-277.	4.2	5

#	Article	IF	Citations
109	Uneven distribution of protein kinase C-? and -? isozymes in human sarcomas and carcinomas. Journal of Cellular Physiology, 1994, 159, 434-440.	4.1	5
110	Increased tyrosine phosphorylation in rat transformed fibroblasts occurs prior to manifestation of the transformed phenotype. Biochemical and Biophysical Research Communications, 1990, 170, 526-532.	2.1	4
111	WIP Modulates Oxidative Stress through NRF2/KEAP1 in Glioblastoma Cells. Antioxidants, 2020, 9, 773.	5.1	4
112	Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinsonâ€™s Disease. Antioxidants, 2022, 11, 247.	5.1	4
113	Response to I. Batinic-Haberle et al.. Antioxidants and Redox Signaling, 2016, 24, 525-526.	5.4	0
114	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. SSRN Electronic Journal, 0, , .	0.4	0